Maia Biotechnology Inc (MAIA)

$1.52 -0.05 (-3.18%)
Market Cap 46.07M
Revenue (ttm) 0.00
Net Income (ttm) -23.25M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 236,200
Avg Vol 456,394
Day's Range N/A - N/A
Shares Out 30.31M
Stochastic %K 12%
Beta 0.02
Analysts Strong Sell
Price Target $14.00

Company Profile

MAIA Biotechnology, Inc., together with its subsidiaries, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer. Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.

Industry: Biotechnology
Sector: Healthcare
Phone: 312-416-8592
Address:
444 West Lake Street, Suite 1700, Chicago, United States
OkIGuess
OkIGuess Aug. 1 at 3:06 PM
$MAIA Markets are bleeding because of tariffs today. Nothing more nothing less
0 · Reply
MoneyHelix
MoneyHelix Jul. 31 at 10:45 PM
$MAIA The Fast Track Designation is likely going to attract the interest of Merk, Astrazeneca, BMS, and Pfizer. MAIA's egulatory risk is collapsing 🥂
0 · Reply
DiamondDog33
DiamondDog33 Jul. 31 at 2:10 PM
$MAIA MONEY HELIX just doesnt get it ... No cash Large scale Trial. WARRANTS OUT THE KAZOOOOOOO..<<<< V never hits a Timeline ...lol 1.25
0 · Reply
MoneyHelix
MoneyHelix Jul. 29 at 6:59 PM
$MAIA As for funding, MAIA is caught between a rock and a hard place. They need to continue raising capital at the lower stock price, or secure a co-development deal. Deal-making is hot right now, and it will only continue because of the impending patent cliffs, massive cash balances, and massive cash flow in Big Pharma. THIO is a late-stage, first-in class, oncology small molecule that synergizes with CPIs, and the FDA is recognizing it's potential non-stop. The acquisition potential behind it is enormous. As we move deeper into Phase 2C/D and Phase 3, MAIA should start to see significant acquisition interest if Big Pharma is paying attention.
1 · Reply
MoneyHelix
MoneyHelix Jul. 29 at 6:47 PM
$MAIA Truly dumbfounding price action. Not only did MAIA fail to gain anything yesterday on the FDA Fast Track News, but it's also dropping in price today. This means there was an equal amount of supply and demand for the stock yesterday, and today supply is exceeding demand. Investors in the market have concluded that Value was DESTROYED with the FDA Fast Track. To anyone with a brain, this is obviously an absurd conclusion, but that's what the market is saying! MAIA is becoming a significant acquisition target now with: 1) 3x ODDs 2) 3x Clinical Supply agreements 3) Breakthrough Therapy Designation 4) FDA Fast Track Designation for 3L NSCLC. For whatever reason, the market isn't recognizing the value in MAIA. My hypothesis is that investors are too caught up with AI and crypto, leaving biotech assets overlooked. This is good for patient investors adding at these levels. It's important to also keep in mind that THIO is a small molecule, making manufacturing far easier than biologics.
0 · Reply
Stocks4thought
Stocks4thought Jul. 29 at 5:03 PM
$MAIA fONZ EATING ASK- Nobody on the bid- except vlad?
0 · Reply
GoImugene
GoImugene Jul. 29 at 11:47 AM
$MAIA In 6 months this will be higher. It’s a buy currently.
0 · Reply
GISBlaster98
GISBlaster98 Jul. 29 at 10:27 AM
$MAIA It is very perplexing to me … why the stick price didn’t zoom on the news. However that being said …. The news certainly is significant and I really like what the future holds for the long term shareholders!
1 · Reply
Ilikethestock89
Ilikethestock89 Jul. 29 at 10:11 AM
$MAIA Hi that approved fast track almost didnt move with stock. How it so ? im few months in to Bio stocks and see some things can moves stock about 100s% and some barely few %.
0 · Reply
share97
share97 Jul. 28 at 8:52 PM
$MAIA I gotta say, this is big news to me. Idc what market does. Good work team.
0 · Reply
Latest News on MAIA
MAIA Biotechnology Receives FDA's Fast Track Designation for Ateganosine as a Treatment for Non-Small Cell Lung Cancer

Jul 28, 2025, 8:01 AM EDT - 6 days ago

MAIA Biotechnology Receives FDA's Fast Track Designation for Ateganosine as a Treatment for Non-Small Cell Lung Cancer

MAIA Biotechnology Announces Peer-Reviewed Journal Publication of Data Validating Second Generation Ateganosine Prodrugs for Anticancer Therapy

Jul 17, 2025, 9:17 AM EDT - 17 days ago

MAIA Biotechnology Announces Peer-Reviewed Journal Publication of Data Validating Second Generation Ateganosine Prodrugs for Anticancer Therapy

MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer

Jul 9, 2025, 9:15 AM EDT - 25 days ago

MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer

MAIA Biotechnology to Present Two Posters Featuring Cancer Telomere-Targeting Agents at FEBS 2025 Congress

Jul 1, 2025, 9:00 AM EDT - 4 weeks ago

MAIA Biotechnology to Present Two Posters Featuring Cancer Telomere-Targeting Agents at FEBS 2025 Congress

MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board

Jun 24, 2025, 8:15 AM EDT - 5 weeks ago

MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board

MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies

Jun 18, 2025, 9:15 AM EDT - 6 weeks ago

MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies

MAIA Biotechnology to Present at BIO International Convention 2025

Jun 10, 2025, 8:46 AM EDT - 7 weeks ago

MAIA Biotechnology to Present at BIO International Convention 2025

MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients

Jun 5, 2025, 2:28 PM EDT - 2 months ago

MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients

MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial

Jun 5, 2025, 11:10 AM EDT - 2 months ago

MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial

MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer

Jun 5, 2025, 8:04 AM EDT - 2 months ago

MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer

CORRECTING and REPLACING MAIA Biotechnology Announces Private Placement of Approximately $695,000

May 27, 2025, 5:35 PM EDT - 2 months ago

CORRECTING and REPLACING MAIA Biotechnology Announces Private Placement of Approximately $695,000

MAIA Biotechnology Announces Private Placement of Approximately $669,500

May 27, 2025, 4:30 PM EDT - 2 months ago

MAIA Biotechnology Announces Private Placement of Approximately $669,500

MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

May 15, 2025, 11:05 AM EDT - 2 months ago

MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

MAIA Biotechnology Announces Director Participation in Recent Private Placement

May 14, 2025, 10:15 AM EDT - 2 months ago

MAIA Biotechnology Announces Director Participation in Recent Private Placement

CORRECTION: MAIA Biotechnology Announces $1.08 Million Private Placement

May 5, 2025, 11:45 PM EDT - 3 months ago

CORRECTION: MAIA Biotechnology Announces $1.08 Million Private Placement

MAIA Biotechnology Announces $1.08 Million Private Placement

May 5, 2025, 4:05 PM EDT - 3 months ago

MAIA Biotechnology Announces $1.08 Million Private Placement

MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders

Apr 1, 2025, 8:30 AM EDT - 4 months ago

MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders

MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025

Mar 25, 2025, 8:46 AM EDT - 4 months ago

MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025

MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug

Mar 20, 2025, 9:20 AM EDT - 4 months ago

MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug

MAIA Biotechnology Receives USAN Council Approval for “Ateganosine” as Nonproprietary Name for Anticancer Agent THIO

Mar 19, 2025, 11:00 AM EDT - 4 months ago

MAIA Biotechnology Receives USAN Council Approval for “Ateganosine” as Nonproprietary Name for Anticancer Agent THIO

MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients

Feb 27, 2025, 8:51 AM EST - 5 months ago

MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients

MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer

Feb 26, 2025, 8:47 AM EST - 5 months ago

MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer

MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million

Feb 24, 2025, 4:30 PM EST - 5 months ago

MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million

MAIA Biotechnology Announces Private Placement of $2,715,000

Feb 18, 2025, 3:44 PM EST - 5 months ago

MAIA Biotechnology Announces Private Placement of $2,715,000

MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer

Feb 4, 2025, 8:51 AM EST - 6 months ago

MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer

MAIA Biotechnology to Present at Biotech Showcase 2025

Jan 10, 2025, 9:45 AM EST - 7 months ago

MAIA Biotechnology to Present at Biotech Showcase 2025

MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings

Dec 19, 2024, 8:47 AM EST - 8 months ago

MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings

MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas

Dec 16, 2024, 8:37 AM EST - 8 months ago

MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas

MAIA Biotechnology Announces Private Placement of Approximately $950,000

Dec 9, 2024, 6:00 PM EST - 8 months ago

MAIA Biotechnology Announces Private Placement of Approximately $950,000

MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer

Dec 3, 2024, 8:17 AM EST - 8 months ago

MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer

MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement

Nov 7, 2024, 8:47 AM EST - 9 months ago

MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement

MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Nov 5, 2024, 9:45 AM EST - 9 months ago

MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

MAIA Biotechnology Announces $2.44 Million Private Placement

Oct 28, 2024, 7:00 PM EDT - 9 months ago

MAIA Biotechnology Announces $2.44 Million Private Placement

MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics

Oct 15, 2024, 8:15 AM EDT - 10 months ago

MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics

MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer

Sep 10, 2024, 6:00 AM EDT - 11 months ago

MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer

MAIA Biotechnology to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 8:30 AM EDT - 11 months ago

MAIA Biotechnology to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference

MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients

Jul 23, 2024, 10:38 AM EDT - 1 year ago

MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients

MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent

Jul 23, 2024, 4:11 AM EDT - 1 year ago

MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent

MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA's Approval of a Telomerase Inhibitor Agent Therapy

Jun 7, 2024, 12:31 PM EDT - 1 year ago

MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA's Approval of a Telomerase Inhibitor Agent Therapy

MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent

Jun 6, 2024, 10:07 AM EDT - 1 year ago

MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent

MAIA Biotechnology Reveals New Clinical Data Showing THIO's Strong Efficacy in Non-Small Cell Lung Cancer

Jun 4, 2024, 8:41 AM EDT - 1 year ago

MAIA Biotechnology Reveals New Clinical Data Showing THIO's Strong Efficacy in Non-Small Cell Lung Cancer

MAIA Biotechnology to Present at the BIO International Convention 2024

May 17, 2024, 8:37 AM EDT - 1 year ago

MAIA Biotechnology to Present at the BIO International Convention 2024

MAIA Biotechnology Abstract Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

May 16, 2024, 8:37 AM EDT - 1 year ago

MAIA Biotechnology Abstract Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement

Apr 30, 2024, 8:08 AM EDT - 1 year ago

MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement

MAIA Biotechnology Announces Share Purchase by Director Stan Smith, Ph.D. in Private Placement

Apr 29, 2024, 8:08 AM EDT - 1 year ago

MAIA Biotechnology Announces Share Purchase by Director Stan Smith, Ph.D. in Private Placement

MAIA Biotechnology Announces $1.00 Million Private Placement

Apr 23, 2024, 8:51 AM EDT - 1 year ago

MAIA Biotechnology Announces $1.00 Million Private Placement

MAIA Biotechnology to Present at Two Investor Conferences in April 2024

Apr 5, 2024, 8:01 AM EDT - 1 year ago

MAIA Biotechnology to Present at Two Investor Conferences in April 2024

MAIA Biotechnology Announces Share Purchases by Directors Cristian Luput and Ramiro Guerrero

Mar 28, 2024, 3:00 PM EDT - 1 year ago

MAIA Biotechnology Announces Share Purchases by Directors Cristian Luput and Ramiro Guerrero

MAIA Biotechnology Announces $1.33 Million Private Placement

Mar 26, 2024, 8:01 AM EDT - 1 year ago

MAIA Biotechnology Announces $1.33 Million Private Placement

MAIA Biotechnology Announces Share Purchase by Director Stan Smith, PhD in a $2.9 Million Private Placement

Mar 22, 2024, 3:00 PM EDT - 1 year ago

MAIA Biotechnology Announces Share Purchase by Director Stan Smith, PhD in a $2.9 Million Private Placement

OkIGuess
OkIGuess Aug. 1 at 3:06 PM
$MAIA Markets are bleeding because of tariffs today. Nothing more nothing less
0 · Reply
MoneyHelix
MoneyHelix Jul. 31 at 10:45 PM
$MAIA The Fast Track Designation is likely going to attract the interest of Merk, Astrazeneca, BMS, and Pfizer. MAIA's egulatory risk is collapsing 🥂
0 · Reply
DiamondDog33
DiamondDog33 Jul. 31 at 2:10 PM
$MAIA MONEY HELIX just doesnt get it ... No cash Large scale Trial. WARRANTS OUT THE KAZOOOOOOO..<<<< V never hits a Timeline ...lol 1.25
0 · Reply
MoneyHelix
MoneyHelix Jul. 29 at 6:59 PM
$MAIA As for funding, MAIA is caught between a rock and a hard place. They need to continue raising capital at the lower stock price, or secure a co-development deal. Deal-making is hot right now, and it will only continue because of the impending patent cliffs, massive cash balances, and massive cash flow in Big Pharma. THIO is a late-stage, first-in class, oncology small molecule that synergizes with CPIs, and the FDA is recognizing it's potential non-stop. The acquisition potential behind it is enormous. As we move deeper into Phase 2C/D and Phase 3, MAIA should start to see significant acquisition interest if Big Pharma is paying attention.
1 · Reply
MoneyHelix
MoneyHelix Jul. 29 at 6:47 PM
$MAIA Truly dumbfounding price action. Not only did MAIA fail to gain anything yesterday on the FDA Fast Track News, but it's also dropping in price today. This means there was an equal amount of supply and demand for the stock yesterday, and today supply is exceeding demand. Investors in the market have concluded that Value was DESTROYED with the FDA Fast Track. To anyone with a brain, this is obviously an absurd conclusion, but that's what the market is saying! MAIA is becoming a significant acquisition target now with: 1) 3x ODDs 2) 3x Clinical Supply agreements 3) Breakthrough Therapy Designation 4) FDA Fast Track Designation for 3L NSCLC. For whatever reason, the market isn't recognizing the value in MAIA. My hypothesis is that investors are too caught up with AI and crypto, leaving biotech assets overlooked. This is good for patient investors adding at these levels. It's important to also keep in mind that THIO is a small molecule, making manufacturing far easier than biologics.
0 · Reply
Stocks4thought
Stocks4thought Jul. 29 at 5:03 PM
$MAIA fONZ EATING ASK- Nobody on the bid- except vlad?
0 · Reply
GoImugene
GoImugene Jul. 29 at 11:47 AM
$MAIA In 6 months this will be higher. It’s a buy currently.
0 · Reply
GISBlaster98
GISBlaster98 Jul. 29 at 10:27 AM
$MAIA It is very perplexing to me … why the stick price didn’t zoom on the news. However that being said …. The news certainly is significant and I really like what the future holds for the long term shareholders!
1 · Reply
Ilikethestock89
Ilikethestock89 Jul. 29 at 10:11 AM
$MAIA Hi that approved fast track almost didnt move with stock. How it so ? im few months in to Bio stocks and see some things can moves stock about 100s% and some barely few %.
0 · Reply
share97
share97 Jul. 28 at 8:52 PM
$MAIA I gotta say, this is big news to me. Idc what market does. Good work team.
0 · Reply
DiamondDog33
DiamondDog33 Jul. 28 at 8:32 PM
$MAIA Problem is V and his WARRANTS ....So SO SOOO SOOOOOOOOOO much over head ... Plus cant raise the Coin< Its right there in front of your face ... nice entry 1.25 ....level field with mgmt and their 0 warrants
0 · Reply
aku78
aku78 Jul. 28 at 7:49 PM
$MAIA frustrating!!!
0 · Reply
GISBlaster98
GISBlaster98 Jul. 28 at 5:48 PM
$MAIA 140,000 shares. Long and strong!
0 · Reply
DiamondDog33
DiamondDog33 Jul. 28 at 4:51 PM
$MAIA the PROBLEM here is NO CASH and A VIRTUAL CARGO SHIP OF WARRANTS that V has PERMITTED !!! The overhang of Warrants is absurd..... Good for years of Salary and Bonus though ..LOL Good buy on par with the kings 1.20s ..of course long term.. years to LARGE scale completion .....By then maybe V can get his own PR dept ...rather than outsource to Fl ...
2 · Reply
Leonardo01
Leonardo01 Jul. 28 at 3:19 PM
$MAIA You can do this!!
0 · Reply
douglas423
douglas423 Jul. 28 at 3:00 PM
$MAIA lets it get it moving
0 · Reply
stevenryl86
stevenryl86 Jul. 28 at 2:05 PM
$MAIA horrendous price action with fda fast track
2 · Reply
DiamondDog33
DiamondDog33 Jul. 28 at 1:46 PM
$MAIA NO MONEY FOR LARGE SCALE TRIAL <<<<<<<<<<< A PUMP HERE is only for more WARRANTS to ADD ... THE WARRANT KINGS!
1 · Reply
douglas423
douglas423 Jul. 28 at 1:38 PM
$MAIA added here
0 · Reply
Stocks4thought
Stocks4thought Jul. 28 at 1:37 PM
$MAIA Fonzie still trying to get his ride hubcaps- outz the hood?
0 · Reply
WallStCrush3r
WallStCrush3r Jul. 28 at 1:19 PM
$MAIA $XBI Outstanding news and very tiny float. Adding here . 💰💵 MAIA Biotechnology receives FDA fast track designation for lung cancer drug https://ooc.bz/l/71423
0 · Reply
Panama73
Panama73 Jul. 28 at 1:06 PM
$CELC $AIM $MAIA
0 · Reply